EBS Q4 net loss $1.04/sh, FY2025 net income $0.93/sh; FY2026 rev guidance $720-760M

Emergent BioSolutions Inc.

2025-FY EPS reported $0.93 revenue$742,900,000

Full year 2025 total revenues $742.9M, down 29% from $1,043.6M in 2024.
Q4 2025 net loss $54.6M ($1.04 loss per diluted share), vs Q4 2024 loss $31.3M.
Full year 2025 net income $52.6M ($0.93 diluted EPS), vs prior year net loss $190.6M.
Adjusted EBITDA for FY2025 $205.0M, up 12% from $183.1M in 2024.
FY2026 guidance: revenues $720-760M, adjusted net income $25-45M, adjusted EBITDA $135-155M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.